Research
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target
SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $11.33, according to analysts polled by FactSet.
$SABS
$SABS
4 stories mentioning SABSUpdated 90d ago
Every FINWIRES story that references SABS, newest first.
What are analysts saying about SABS?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on SABS?
Research
Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target
SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $10.30, according to analysts polled by FactSet.
$SABS
Research
Jefferies Initiates SAB Biotherapeutics at Buy With $11 Price Target
SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $10.30, according to analysts polled by FactSet.
$SABS
Wire
Emergent BioSolutions Signs $50 Million Contract to Support SAB Biotherapeutics' Lead Program
Emergent BioSolutions (EBS) said Wednesday it has signed a $50 million multi-year agreement with SAB Biotherapeutics (SABS) to help advance SAB-142 lead program in clinical development for autoimmune type 1 diabetes.Under the agreement, $36 million is contingent on future regulatory approval and downstream milestones, according to a statement.Emergent BioSolutions will provide end-to-end development and manufacturing services that are compliant with current good manufacturing practices, the company said.Price: $8.17, Change: $-0.07, Percent Change: -0.79%
$EBS$SABS
